CD274 and ovarian cancer: However, in preclinical and clinical studies of EC, SCC, ovarian cancer, and non–small cell lung carcinoma,23, 24, 25, 26, 27 higher prevalence of PD‐L1 positivity has been seen in later lines of therapy, particularly in patients who previously received platinum therapy.